

Metastatic triple-negative breast cancer (mTNBC) remains a formidable clinical challenge due to its aggressive biology and historically limited targeted options. This presentation reviews recent advances that define a new therapeutic era for mTNBC, with emphasis on who, when, and why to use immunotherapy and antibody-drug conjugates (ADCs). The session will summarize the current first-line treatment landscape, evaluating efficacy, toxicity profiles, and unmet needs while outlining plausible future directions. It will then examine the biological rationale and emerging clinical evidence supporting combinations of ADCs with immune checkpoint inhibitors (ICIs), highlighting mechanisms by which ADC-mediated tumor cell death and antigen release may potentiate anti-